MiNK Therapeutics Reports MiNK-215 Shows Strong Anti-Tumor Activity in Resistant Solid Tumors
I'm PortAI, I can summarize articles.
MiNK Therapeutics Inc. has announced promising preclinical results for MiNK-215, a novel therapy targeting resistant solid tumors. Published in Cancer Immunology Research, MiNK-215, an IL-15-enhanced, FAP-targeting CAR-iNKT cell therapy, shows strong anti-tumor activity by dismantling tumor-protective barriers and activating immune pathways. It offers a scalable, off-the-shelf treatment option for patients unresponsive to conventional therapies. The original content was published by MiNK Therapeutics via GlobeNewswire on November 20, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments